William R. Wilson
Auckland Cancer Society Research Centre
University of Auckland
Private Bag 92019
Auckland
New Zealand
Name/email consistency: high
- Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy. Gu, Y., Tingle, M.D., Wilson, W.R. J. Pharmacol. Exp. Ther. (2011)
- Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators. Wilson, W.R., Stribbling, S.M., Pruijn, F.B., Syddall, S.P., Patterson, A.V., Liyanage, H.D., Smith, E., Botting, K.J., Tercel, M. Mol. Cancer Ther. (2009)
- Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Wilson, W.R., Hicks, K.O., Pullen, S.M., Ferry, D.M., Helsby, N.A., Patterson, A.V. Radiat. Res. (2007)
- Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Wilson, W.R., Pullen, S.M., Hogg, A., Helsby, N.A., Hicks, K.O., Denny, W.A. Cancer Res. (2002)
- Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Wilson, W.R., Tercel, M., Anderson, R.F., Denny, W.A. Anticancer Drug Des. (1998)
- Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Wilson, W.R., Li, A.E., Cowan, D.S., Siim, B.G. Int. J. Radiat. Oncol. Biol. Phys. (1998)